Comprehensive analysis of the prognostic value and functions of prefoldins in hepatocellular carcinoma

• Published in: Frontiers in molecular biosciences Vol. 9; p. 957001
• Main Authors: Ke, Shanjia, Lu, Shounan, Wang, Chaoqun, Xu, Yanan, Bai, Miaoyu, Yu, Hongjun, Feng, Zhigang, Yin, Bing, Li, Zihao, Huang, Jingjing, Li, Xinglong, Qian, Baolin, Hua, Yongliang, Pan, Shangha, Wu, Yaohua, Ma, Yong
• Format: Journal Article
• Language: English
• Published: Frontiers Media S.A 11.11.2022
• Subjects: bioinformatics analysis; biomarkers; hepatocellular carcinoma; Molecular Biosciences; PFDNs; prognosis
• ISSN: 2296-889X; 2296-889X
• DOI: 10.3389/fmolb.2022.957001

Prefoldins (PFDNs), a group of proteins known to be associated with cytoskeletal rearrangement, are involved in tumor progression in various cancer types. However, little is known about the roles of PFDNs in hepatocellular carcinoma (HCC). Herein, we investigated the transcriptional and survival data of PFDNs from The Cancer Genome Atlas (TCGA) database. Gene Ontology (GO), Gene Set Enrichment Analysis (GSEA), and single-sample gene set enrichment analysis (ssGSEA) were used to evaluate the potential functions of PFDN1/2/3/4. We also detected the expression of PFDN1/2/3/4 via immunohistochemistry (IHC), Western blotting, and real-time PCR in our clinical samples. We found that the PFDN family showed elevated expression in HCC tissues, while only PFDN1/2/3/4 were found to be significantly correlated with poor prognosis of patients with HCC in the TCGA database. Further investigation was associated with PFDN1–4. We found that the expression of PFDN1/2/3/4 was significantly associated with advanced clinicopathologic features. Apart from the TCGA database, IHC, real-time PCR, and immunoblotting identified the overexpression of PFDN1/2/3/4 in HCC tissues and HCC cell lines. Taken together, these results indicated that PFDN1/2/3/4 might be novel prognostic biomarkers and treatment targets for patients with HCC.